Scinai Immunotherapeutics
SCNI
14 hedge funds and large institutions have $389K invested in Scinai Immunotherapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
22% less funds holding
Funds holding: 18 → 14 (-4)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
29% less capital invested
Capital invested by funds: $544K → $389K (-$155K)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$156K |
| 2 |
Renaissance Technologies
New York
|
+$25.1K |
| 3 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
+$8.23K |
| 4 |
APC
Aspire Private Capital
Cornelius,
North Carolina
|
+$1.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$62K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$38K |
| 3 |
Millennium Management
New York
|
-$34K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$25.3K |
| 5 |
Morgan Stanley
New York
|
-$19.6K |
SCNI Hedge Fund Activity: Q2 2022 in Review
14 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2022, worth a combined $389K — down 29% from $544K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SCNI and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Envestnet Asset Management, adding an estimated $156K. The largest seller was Susquehanna International Group, cutting an estimated $62K.
- 14 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2022, down from 18 in Q1 2022.
- Funds reported $389K of Scinai Immunotherapeutics stock for Q2 2022, down 29% quarter-over-quarter.
- 1 fund opened new Scinai Immunotherapeutics positions in Q2 2022 and 5 closed out, a net change of -4 holders.
- The largest Scinai Immunotherapeutics buyer in Q2 2022 was Envestnet Asset Management, an estimated $156K added.
- The largest Scinai Immunotherapeutics seller in Q2 2022 was Susquehanna International Group, an estimated $62K sold.
Based on aggregated 13F filings for Q2 2022.